Generics And Biosimilars Industry Reshaped By Transformations
Annual Top 50 Sees Leading Firms Change Position And New Entrants Join
The latest Generics Bulletin Top 50 ranking of global generics and biosimilars companies sees a new name in the top five amid transformations for some of the leading off-patent players. Meanwhile, a number of mid-level firms shift position and newcomers climb into the bottom of the table.
You may also be interested in...
Samsung Bioepis has struck a US settlement with Johnson & Johnson that will allow partner Sandoz to launch the pair’s SB17 ustekinumab biosimilar to Stelara in early 2025, assuming FDA approval.
Running until 5 December, the Big Give campaign run by UK-based charity International Health Partners is once again doubling the value of donations, this year to support its child oncology programs in Malawi and Cameroon.
Italy’s Olon has opened its new R&D hub in Milan, shortly after announcing plans to expand a key manufacturing facility in India.